178 related articles for article (PubMed ID: 21079744)
21. Discriminating miRNA Profiles between Endometrioid Well- and Poorly-Differentiated Tumours and Endometrioid and Serous Subtypes of Endometrial Cancers.
Kalinkova L; Kajo K; Karhanek M; Wachsmannova L; Suran P; Zmetakova I; Fridrichova I
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842533
[TBL] [Abstract][Full Text] [Related]
22. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
23. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
24. Laser capture microdissection with genome-wide expression profiling displayed gene expression signatures in endometrioid endometrial cancer.
Mokhtar NM; Ramzi NH; Yin-Ling W; Rose IM; Hatta Mohd Dali AZ; Jamal R
Cancer Invest; 2012 Feb; 30(2):156-64. PubMed ID: 22122087
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
27. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.
Wong YF; Cheung TH; Lo KW; Yim SF; Siu NS; Chan SC; Ho TW; Wong KW; Yu MY; Wang VW; Li C; Gardner GJ; Bonome T; Johnson WB; Smith DI; Chung TK; Birrer MJ
Oncogene; 2007 Mar; 26(13):1971-82. PubMed ID: 17043662
[TBL] [Abstract][Full Text] [Related]
28. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
29. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
30. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
32. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Herrmann FR; Rai H; Tchabo N; Lele S; Izevbaye I; Odunsi K; Cheney RT
Am J Clin Pathol; 2010 Jun; 133(6):899-908. PubMed ID: 20472848
[TBL] [Abstract][Full Text] [Related]
33. Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
Lawrenson K; Pakzamir E; Liu B; Lee JM; Delgado MK; Duncan K; Gayther SA; Liu S; Roman L; Mhawech-Fauceglia P
PLoS One; 2015; 10(7):e0130909. PubMed ID: 26132201
[TBL] [Abstract][Full Text] [Related]
34. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas.
Moreno-Bueno G; Sánchez-Estévez C; Cassia R; Rodríguez-Perales S; Díaz-Uriarte R; Domínguez O; Hardisson D; Andujar M; Prat J; Matias-Guiu X; Cigudosa JC; Palacios J
Cancer Res; 2003 Sep; 63(18):5697-702. PubMed ID: 14522886
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
Lee L; Howitt B; Cheng T; King M; Stawiski K; Fendler W; Chowdhury D; Matulonis U; Konstantinopoulos PA
Gynecol Oncol; 2021 Dec; 163(3):453-458. PubMed ID: 34607711
[TBL] [Abstract][Full Text] [Related]
36. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
37. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
38. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
39. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
Jones NL; Xiu J; Chatterjee-Paer S; Buckley de Meritens A; Burke WM; Tergas AI; Wright JD; Hou JY
Int J Cancer; 2017 Mar; 140(6):1396-1404. PubMed ID: 27905110
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA signatures differentiate uterine cancer tumor subtypes.
Ratner ES; Tuck D; Richter C; Nallur S; Patel RM; Schultz V; Hui P; Schwartz PE; Rutherford TJ; Weidhaas JB
Gynecol Oncol; 2010 Sep; 118(3):251-7. PubMed ID: 20542546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
